GlobeImmune (GBIM) Files $69M IPO
Tweet
Share
E-mail
GlobeImmune, Inc. (Nasdaq: GBIM) filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering price is $69 million. GlobeImmune applied to list on the Nasdaq Global Market under the ticker, "GBIM."
The offering is being made through Wells Fargo Securities, Piper Jaffray, and JMP Securities.
GlobeImmune is a biopharmaceutical company focused on developing therapeutic products for cancer and infectious diseases based on our proprietary Tarmogen platform.
The offering is being made through Wells Fargo Securities, Piper Jaffray, and JMP Securities.
GlobeImmune is a biopharmaceutical company focused on developing therapeutic products for cancer and infectious diseases based on our proprietary Tarmogen platform.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bending Spoons closes IPO, raises ~$954M on Nasdaq
- FST Corp. launches $10.4M at-the-market equity offering
- IES Holdings (IESC) files mixed shelf
Create E-mail Alert Related Categories
IPOsRelated Entities
Piper Jaffray, JMP Securities, Wells FargoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
